Tipranavir
Encyclopedia
Tipranavir, or tipranavir disodium, is a nonpeptidic protease inhibitor
(PI) manufactured by Boehringer-Ingelheim
under the trade name Aptivus. It is administered with ritonavir
in combination therapy to treat HIV
infection and is given as two 250 mg capsules together with 200 mg of ritonavir twice daily.
Tipranavir has the ability to inhibit the replication of virus
es that are resistant to other protease inhibitors and it recommended for patients who are resistant to other treatments. Resistance to tipranavir itself seems to require multiple mutations.
Tipranavir was approved by the Food and Drug Administration
(FDA) on June 22, 2005, and was approved for pediatric use on June 24, 2008. Like lopinavir
and atazanavir
, it is very potent and is effective in salvage therapy for patients with some drug resistance. However, side effects of tipranavir can be more severe than other anti-retrovirals. Some side effects include intracranial hemorraging, hepatitis, and diabetes mellitus. The drug has also been shown to cause increases in total cholesterol and triglycerides.
Protease inhibitor (pharmacology)
Protease inhibitors are a class of drugs used to treat or prevent infection by viruses, including HIV and Hepatitis C. PIs prevent viral replication by inhibiting the activity of proteases, e.g.HIV-1 protease, enzymes used by the viruses to cleave nascent proteins for final assembly of new...
(PI) manufactured by Boehringer-Ingelheim
Boehringer-Ingelheim
C.H. Boehringer Sohn AG & Ko. KG is the parent company of Boehringer Ingelheim, which was founded in 1885 by Albert Boehringer in Ingelheim am Rhein. The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally...
under the trade name Aptivus. It is administered with ritonavir
Ritonavir
Ritonavir, with trade name Norvir , is an antiretroviral drug from the protease inhibitor class used to treat HIV infection and AIDS....
in combination therapy to treat HIV
HIV
Human immunodeficiency virus is a lentivirus that causes acquired immunodeficiency syndrome , a condition in humans in which progressive failure of the immune system allows life-threatening opportunistic infections and cancers to thrive...
infection and is given as two 250 mg capsules together with 200 mg of ritonavir twice daily.
Tipranavir has the ability to inhibit the replication of virus
Virus
A virus is a small infectious agent that can replicate only inside the living cells of organisms. Viruses infect all types of organisms, from animals and plants to bacteria and archaea...
es that are resistant to other protease inhibitors and it recommended for patients who are resistant to other treatments. Resistance to tipranavir itself seems to require multiple mutations.
Tipranavir was approved by the Food and Drug Administration
Food and Drug Administration
The Food and Drug Administration is an agency of the United States Department of Health and Human Services, one of the United States federal executive departments...
(FDA) on June 22, 2005, and was approved for pediatric use on June 24, 2008. Like lopinavir
Lopinavir
Lopinavir is an antiretroviral of the protease inhibitor class. It is used as a fixed-dose combination with another protease inhibitor, ritonavir, under the trade names Kaletra and Aluvia ....
and atazanavir
Atazanavir
Atazanavir, marketed under the trade name Reyataz by Bristol Myers, is an antiretroviral drug of the protease inhibitor class...
, it is very potent and is effective in salvage therapy for patients with some drug resistance. However, side effects of tipranavir can be more severe than other anti-retrovirals. Some side effects include intracranial hemorraging, hepatitis, and diabetes mellitus. The drug has also been shown to cause increases in total cholesterol and triglycerides.